{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:25:04Z","timestamp":1780496704967,"version":"3.54.1"},"reference-count":87,"publisher":"MDPI AG","issue":"19","license":[{"start":{"date-parts":[[2022,9,26]],"date-time":"2022-09-26T00:00:00Z","timestamp":1664150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Georgia Institute of Technology President\u2019s Undergraduate","award":["467"],"award-info":[{"award-number":["467"]}]},{"name":"Georgia Institute of Technology President\u2019s Undergraduate","award":["R21CA232249"],"award-info":[{"award-number":["R21CA232249"]}]},{"name":"Georgia Institute of Technology President\u2019s Undergraduate","award":["1944247"],"award-info":[{"award-number":["1944247"]}]},{"name":"Incyte pharmaceuticals","award":["467"],"award-info":[{"award-number":["467"]}]},{"name":"Incyte pharmaceuticals","award":["R21CA232249"],"award-info":[{"award-number":["R21CA232249"]}]},{"name":"Incyte pharmaceuticals","award":["1944247"],"award-info":[{"award-number":["1944247"]}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["467"],"award-info":[{"award-number":["467"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R21CA232249"],"award-info":[{"award-number":["R21CA232249"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["1944247"],"award-info":[{"award-number":["1944247"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Children\u2019s Hospital of Atlanta Aflac","award":["467"],"award-info":[{"award-number":["467"]}]},{"name":"Children\u2019s Hospital of Atlanta Aflac","award":["R21CA232249"],"award-info":[{"award-number":["R21CA232249"]}]},{"name":"Children\u2019s Hospital of Atlanta Aflac","award":["1944247"],"award-info":[{"award-number":["1944247"]}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation CAREER","doi-asserted-by":"publisher","award":["467"],"award-info":[{"award-number":["467"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation CAREER","doi-asserted-by":"publisher","award":["R21CA232249"],"award-info":[{"award-number":["R21CA232249"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation CAREER","doi-asserted-by":"publisher","award":["1944247"],"award-info":[{"award-number":["1944247"]}],"id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Tyrosine kinase inhibitors (TKIs) are prescribed for chronic myeloid leukemia (CML) and some other cancers. The objective was to predict and rank TKI-related adverse events (AEs), including under-reported or preclinical AEs, using novel text mining. First, k-means clustering of 2575 clinical CML TKI abstracts separated TKIs by significant (p &lt; 0.05) AE type: gastrointestinal (bosutinib); edema (imatinib); pulmonary (dasatinib); diabetes (nilotinib); cardiovascular (ponatinib). Next, we propose a novel cross-domain text mining method utilizing a knowledge graph, link prediction, and hub node network analysis to predict new relationships. Cross-domain text mining of 30+ million articles via SemNet predicted and ranked known and novel TKI AEs. Three physiology-based tiers were formed using unsupervised rank aggregation feature importance. Tier 1 ranked in the top 1%: hematology (anemia, neutropenia, thrombocytopenia, hypocellular marrow); glucose (diabetes, insulin resistance, metabolic syndrome); iron (deficiency, overload, metabolism), cardiovascular (hypertension, heart failure, vascular dilation); thyroid (hypothyroidism, hyperthyroidism, parathyroid). Tier 2 ranked in the top 5%: inflammation (chronic inflammatory disorder, autoimmune, periodontitis); kidney (glomerulonephritis, glomerulopathy, toxic nephropathy). Tier 3 ranked in the top 10%: gastrointestinal (bowel regulation, hepatitis, pancreatitis); neuromuscular (autonomia, neuropathy, muscle pain); others (secondary cancers, vitamin deficiency, edema). Results suggest proactive TKI patient AE surveillance levels: regular surveillance for tier 1, infrequent surveillance for tier 2, and symptom-based surveillance for tier 3.<\/jats:p>","DOI":"10.3390\/cancers14194686","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T21:23:27Z","timestamp":1664313807000},"page":"4686","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Cross-Domain Text Mining to Predict Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia"],"prefix":"10.3390","volume":"14","author":[{"given":"Nidhi","family":"Mehra","sequence":"first","affiliation":[{"name":"Laboratory for Pathology Dynamics, Department of Biomedical Engineering, Georgia Institute of Technology, Emory University School of Medicine, Atlanta, GA 30332, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armon","family":"Varmeziar","sequence":"additional","affiliation":[{"name":"Laboratory for Pathology Dynamics, Department of Biomedical Engineering, Georgia Institute of Technology, Emory University School of Medicine, Atlanta, GA 30332, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6769-3046","authenticated-orcid":false,"given":"Xinyu","family":"Chen","sequence":"additional","affiliation":[{"name":"Laboratory for Pathology Dynamics, Department of Biomedical Engineering, Georgia Institute of Technology, Emory University School of Medicine, Atlanta, GA 30332, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia","family":"Kronick","sequence":"additional","affiliation":[{"name":"Laboratory for Pathology Dynamics, Department of Biomedical Engineering, Georgia Institute of Technology, Emory University School of Medicine, Atlanta, GA 30332, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Fisher","sequence":"additional","affiliation":[{"name":"Laboratory for Pathology Dynamics, Department of Biomedical Engineering, Georgia Institute of Technology, Emory University School of Medicine, Atlanta, GA 30332, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5290-9289","authenticated-orcid":false,"given":"Vamsi","family":"Kota","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Georgia Cancer Center, Augusta University, Augusta, GA 30912, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassie S.","family":"Mitchell","sequence":"additional","affiliation":[{"name":"Laboratory for Pathology Dynamics, Department of Biomedical Engineering, Georgia Institute of Technology, Emory University School of Medicine, Atlanta, GA 30332, USA"},{"name":"Center for Machine Learning, Georgia Institute of Technology, Atlanta, GA 30332, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,26]]},"reference":[{"key":"ref_1","unstructured":"SEER (2022, March 23). Chronic Myeloid Leukemia\u2014Cancer Stat Facts, Available online: https:\/\/seer.cancer.gov\/statfacts\/html\/cmyl.html."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Athale, U., Hijiya, N., Patterson, B.C., Bergsagel, J., Andolina, J.R., Bittencourt, H., Schultz, K.R., Burke, M.J., Redell, M.S., and Kolb, E.A. (2019). Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children\u2019s Oncology Group CML Working Group. Pediatr. Blood Cancer, 66.","DOI":"10.1002\/pbc.27827"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.21873\/anticanres.14215","article-title":"ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives","volume":"40","author":"Massimino","year":"2020","journal-title":"Anticancer Res."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s12185-017-2295-0","article-title":"Treatment-free remission in patients with chronic myeloid leukemia","volume":"108","author":"Rea","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1007\/s11899-021-00653-1","article-title":"Treatment-Free Remission: The New Goal in CML Therapy","volume":"16","author":"Atallah","year":"2021","journal-title":"Curr. Hematol. Malig. Rep."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1158\/1078-0432.CCR-13-1988","article-title":"Deep molecular response in chronic myeloid leukemia: The new goal of therapy?","volume":"20","author":"Mahon","year":"2014","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/ajh.25342","article-title":"Treatment-free remission with first- and second-generation tyrosine kinase inhibitors","volume":"94","author":"Cortes","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","article-title":"Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years","volume":"109","author":"Rousselot","year":"2007","journal-title":"Blood"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1182\/blood-2013-02-483750","article-title":"Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: Results from the TWISTER study","volume":"122","author":"Ross","year":"2013","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): A prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s00432-018-2604-x","article-title":"Durable treatment-free remission in patients with chronic myeloid leukemia in chronic phase following frontline nilotinib: 96-week update of the ENESTfreedom study","volume":"144","author":"Ross","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1038\/s41375-021-01260-y","article-title":"Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update","volume":"35","author":"Hughes","year":"2021","journal-title":"Leukemia"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/10428194.2019.1675879","article-title":"Dasatinib discontinuation in patients with chronic-phase chronic myeloid leukemia and stable deep molecular response: The DASFREE study","volume":"61","author":"Shah","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e398","DOI":"10.1016\/S2352-3026(19)30087-0","article-title":"Treatment value of second-generation BCR-ABL1 tyrosine kinase inhibitors compared with imatinib to achieve treatment-free remission in patients with chronic myeloid leukaemia: A modelling study","volume":"6","author":"Shih","year":"2019","journal-title":"Lancet Haematol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1177\/1078155219864640","article-title":"Front-line use of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia: Practice considerations","volume":"26","author":"Reff","year":"2020","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Mohanavelu, P., Mutnick, M., Mehra, N., White, B., Kudrimoti, S., Hernandez Kluesner, K., Chen, X., Nguyen, T., Horlander, E., and Thenot, H. (2021). Meta-Analysis of Gastrointestinal Adverse Events from Tyrosine Kinase Inhibitors for Chronic Myeloid Leukemia. Cancers, 13.","DOI":"10.3390\/cancers13071643"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/bloodadvances.2019000268","article-title":"Side-effects profile and outcomes of ponatinib in the treatment of chronic myeloid leukemia","volume":"4","author":"Chan","year":"2020","journal-title":"Blood Adv."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2040620720966120","DOI":"10.1177\/2040620720966120","article-title":"Tyrosine kinase inhibitors and pregnancy in chronic myeloid leukemia: Opinion, evidence, and recommendations","volume":"11","author":"Abruzzese","year":"2020","journal-title":"Ther. Adv. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1182\/asheducation-2013.1.168","article-title":"Which TKI? An embarrassment of riches for chronic myeloid leukemia patients","volume":"2013","author":"Hughes","year":"2013","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1038\/leu.2016.104","article-title":"European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1182\/blood-2011-08-358135","article-title":"Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: A single-institution historical experience","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Kirkpatrick, A.O.C., Kartchner, D., Allegri, S., Nakajima An, D., McCoy, K., Davalbhakta, E., and Mitchell, C.S. (2022). Optimizations for Computing Relatedness in Biomedical Heterogeneous Information Networks: SemNet 2.0. Big Data Cogn. Comput., 6.","DOI":"10.3390\/bdcc6010027"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"156","DOI":"10.3389\/fbioe.2019.00156","article-title":"SemNet: Using Local Features to Navigate the Biomedical Concept Graph","volume":"7","author":"Sedler","year":"2019","journal-title":"Front. Bioeng. Biotechnol."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Xiao, Y., Zhang, B., Cloyd, J.M., Alaimo, L., Xu, G., Du, S., Mao, Y., and Pawlik, T.M. (2022). Novel Drug Candidate Prediction for Intrahepatic Cholangiocarcinoma via Hub Gene Network Analysis and Connectivity Mapping. Cancers, 14.","DOI":"10.3390\/cancers14133284"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Wu, Z.W., Gao, Z.R., Liang, H., Fang, T., Wang, Y., Du, Z.Q., and Yang, C.X. (2022). Network analysis reveals different hub genes and molecular pathways for pig in vitro fertilized early embryos and parthenogenotes. Reprod. Domest. Anim., 1\u201310.","DOI":"10.1111\/rda.14231"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Nemati, M., Zare, N., Hedayat-Evrigh, N., and Asghari, R. (2022). Identification of Key Gene Network Modules and Hub Genes Associated with Wheat Response to Biotic Stress Using Combined Microarray Meta-analysis and WGCN Analysis. Mol. Biotechnol., Online ahead of print.","DOI":"10.1007\/s12033-022-00541-w"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s13042-010-0001-0","article-title":"Understanding bag-of-words model: A statistical framework","volume":"1","author":"Zhang","year":"2010","journal-title":"Int. J. Mach. Learn. Cybern."},{"key":"ref_28","unstructured":"MacQueen, J. (July, January 21). Some methods for classification and analysis of multivariate observations. Proceedings of the Fifth Berkeley Symposium on Mathematical Statistics and Probability, Berkeley, CA, USA."},{"key":"ref_29","first-page":"2825","article-title":"Scikit-learn: Machine Learning in Python","volume":"12","author":"Pedregosa","year":"2011","journal-title":"J. Mach. Learn. Res."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"McCoy, K., Gudapati, S., He, L., Horlander, E., Kartchner, D., Kulkarni, S., Mehra, N., Prakash, J., Thenot, H., and Vanga, S.V. (2021). Biomedical Text Link Prediction for Drug Discovery: A Case Study with COVID-19. Pharmaceutics, 13.","DOI":"10.3390\/pharmaceutics13060794"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Huang, Z.A., Huang, Y.A., You, Z.H., Zhu, Z., and Sun, Y. (2018). Novel link prediction for large-scale miRNA-lncRNA interaction network in a bipartite graph. BMC Med. Genom., 11.","DOI":"10.1186\/s12920-018-0429-8"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3389\/fdata.2019.00015","article-title":"Applying Answer Set Programming for Knowledge-Based Link Prediction on Social Interaction Networks","volume":"2","author":"Guven","year":"2019","journal-title":"Front. Big Data"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Crichton, G., Guo, Y., Pyysalo, S., and Korhonen, A. (2018). Neural networks for link prediction in realistic biomedical graphs: A multi-dimensional evaluation of graph embedding-based approaches. BMC Bioinform., 19.","DOI":"10.1186\/s12859-018-2163-9"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S2213-8587(21)00139-X","article-title":"Imatinib therapy for patients with recent-onset type 1 diabetes: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"9","author":"Gitelman","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.tem.2015.09.003","article-title":"Tyrosine Kinase Inhibitors and Diabetes: A Novel Treatment Paradigm?","volume":"26","author":"Fountas","year":"2015","journal-title":"Trends Endocrinol. Metab."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s13105-015-0428-6","article-title":"Amelioration of experimentally induced diabetic nephropathy and renal damage by nilotinib","volume":"71","author":"Elsherbiny","year":"2015","journal-title":"J. Physiol. Biochem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"172569","DOI":"10.1016\/j.ejphar.2019.172569","article-title":"Nilotinib enhances beta-islets integrity and secretory functions in a rat model of STZ-induced diabetes mellitus","volume":"860","author":"Samaha","year":"2019","journal-title":"Eur. J. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.critrevonc.2011.08.002","article-title":"Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: Open questions","volume":"82","author":"Valent","year":"2012","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.1007\/s00508-015-0931-3","article-title":"Diabetes mellitus: Definition, classification and diagnosis","volume":"128","author":"Roden","year":"2016","journal-title":"Wien. Klin. Wochenschr."},{"key":"ref_40","first-page":"119","article-title":"Chronic anemia and thyroid function","volume":"88","author":"Soliman","year":"2017","journal-title":"Acta Bio-Med. Atenei Parm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"357","DOI":"10.3904\/kjim.2015.024","article-title":"Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells","volume":"31","author":"Kim","year":"2016","journal-title":"Korean J. Intern Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.blre.2018.01.004","article-title":"Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing","volume":"32","author":"Medeiros","year":"2018","journal-title":"Blood Rev."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1182\/bloodadvances.2018025874","article-title":"Analysis of cardiovascular and arteriothrombotic adverse events in chronic-phase CML patients after frontline TKIs","volume":"3","author":"Jain","year":"2019","journal-title":"Blood Adv."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1182\/hematology.2021000239","article-title":"Lifelong TKI therapy: How to manage cardiovascular and other risks","volume":"2021","author":"Mauro","year":"2021","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"725410","DOI":"10.1155\/2013\/725410","article-title":"Tyrosine kinase inhibitors induced thyroid dysfunction: A review of its incidence, pathophysiology, clinical relevance, and treatment","volume":"2013","author":"Ahmadieh","year":"2013","journal-title":"BioMed Res. Int."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"E332","DOI":"10.1002\/ajh.25997","article-title":"BCR-ABL1 tyrosine kinase inhibitor-associated thyroid dysfunction: A review of cases reported to the FDA Adverse Event Reporting System and published in the literature","volume":"95","author":"Patel","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1111\/j.1365-2257.2006.00877.x","article-title":"Pancytopenia and secondary myelofibrosis could be induced by primary hyperparathyroidism","volume":"29","author":"Lim","year":"2007","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.bone.2011.04.014","article-title":"The skeletal effects of the tyrosine kinase inhibitor nilotinib","volume":"49","author":"Lin","year":"2011","journal-title":"Bone"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"F721","DOI":"10.1152\/ajprenal.00141.2017","article-title":"Src family kinases in chronic kidney disease","volume":"313","author":"Wang","year":"2017","journal-title":"Am. J. Physiol. Ren. Physiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1681\/ASN.2010111158","article-title":"Nilotinib attenuates renal injury and prolongs survival in chronic kidney disease","volume":"22","author":"Iyoda","year":"2011","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clml.2015.12.003","article-title":"Clinical Safety and Efficacy of Nilotinib or Dasatinib in Patients with Newly Diagnosed Chronic-Phase Chronic Myelogenous Leukemia and Pre-Existing Liver and\/or Renal Dysfunction","volume":"16","author":"Sasaki","year":"2016","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1002\/cncr.25071","article-title":"Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and\/or renal dysfunction","volume":"116","author":"Tong","year":"2010","journal-title":"Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"ElShaer, A., Almasry, M., Alawar, M., Masoud, H., and El Kinge, A.R. (2021). Dasatinib-Induced Nephrotic Syndrome: A Case Report. Cureus, 13.","DOI":"10.7759\/cureus.20330"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1756-8722-2-46","article-title":"The occurrence and management of fluid retention associated with TKI therapy in CML, with a focus on dasatinib","volume":"2","author":"Masiello","year":"2009","journal-title":"J. Hematol. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Hailan, Y.M., Elyas, A., Abdulla, M.A., and Yassin, M.A. (2021). Dasatinib-Induced Pleural and Pericardial Effusions. Cureus, 13.","DOI":"10.7759\/cureus.19024"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/leu.2016.59","article-title":"Increased prevalence of prior malignancies and autoimmune diseases in patients diagnosed with chronic myeloid leukemia","volume":"30","author":"Gunnarsson","year":"2016","journal-title":"Leukemia"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"106310","DOI":"10.1016\/j.leukres.2020.106310","article-title":"Plasma proteomics of biomarkers for inflammation or cancer cannot predict relapse in chronic myeloid leukaemia patients stopping tyrosine kinase inhibitor therapy","volume":"90","author":"Soderlund","year":"2020","journal-title":"Leuk. Res."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Oshima, N., Mishima, Y., Shibagaki, K., Kawashima, K., Ishimura, N., Ikejiri, F., Onishi, C., Okada, T., Inoue, M., and Moriyama, I. (2021). Differential gene expression analysis of dasatinib-induced colitis in a patient with chronic myeloid leukemia followed for 3 years: A case report. BMC Gastroenterol., 21.","DOI":"10.1186\/s12876-020-01584-6"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"72311","DOI":"10.18632\/oncotarget.11100","article-title":"Genetic predisposition and induced pro-inflammatory\/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients","volume":"7","author":"Bocchia","year":"2016","journal-title":"Oncotarget"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.transci.2018.02.003","article-title":"Dasatinib-induced immune mediated-thrombotic thrombocytopenic purpura","volume":"57","author":"Demirsoy","year":"2018","journal-title":"Transfus. Apher. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Ptasiewicz, M., Maksymiuk, P., and Chalas, R. (2022). Oral Hygiene Considerations in Adult Patients with Leukemia during a Cycle of Chemotherapy. Int. J. Environ. Res. Public Health, 19.","DOI":"10.3390\/ijerph19010479"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"486","DOI":"10.4103\/0970-9290.74212","article-title":"Estimation of salivary amylase and total proteins in leukemia patients and its correlation with clinical feature and radiographic finding","volume":"21","author":"Ashok","year":"2010","journal-title":"Indian J. Dent. Res."},{"key":"ref_63","first-page":"38","article-title":"Poor Oral Health Linked with Increased Risk of Infectious Complications in Adults with Leukemia","volume":"64","author":"Allareddy","year":"2015","journal-title":"J. Mass. Dent. Soc."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Wang, Z., Wang, X., Wang, Z., Feng, Y., Jia, Y., Jiang, L., Xia, Y., Cao, J., and Liu, Y. (2021). Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients with Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis. JAMA Netw. Open, 4.","DOI":"10.1001\/jamanetworkopen.2021.20165"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12185-013-1474-x","article-title":"Treatment with dasatinib for chronic myeloid leukemia following imatinib-induced hepatotoxicity","volume":"99","author":"Harbaum","year":"2014","journal-title":"Int. J. Hematol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s11010-022-04376-6","article-title":"Transport and metabolism of tyrosine kinase inhibitors associated with chronic myeloid leukemia therapy: A review","volume":"477","author":"Kumar","year":"2022","journal-title":"Mol. Cell Biochem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1080\/10428194.2019.1627536","article-title":"The influence of salivary amylase on total amylase elevation in CML patients treated with TKI therapy: A case series of 3 patients","volume":"60","author":"Nesr","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1177\/1060028013501144","article-title":"Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"47","author":"Shamroe","year":"2013","journal-title":"Ann. Pharmacother."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Sasi, S., Mohamed, M., Chitrambika, P., and Yassin, M. (2022). Myasthenia Gravis and Myeloproliferative Neoplasms\u2014Mere Association or Paraneoplastic Neurologic Syndrome: A Mini-Review. Acta Bio-Med. Atenei Parm., 92.","DOI":"10.22541\/au.161525501.12600394\/v1"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1007\/s12185-017-2339-5","article-title":"Dasatinib-associated reversible demyelinating peripheral polyneuropathy in a case of chronic myeloid leukemia","volume":"107","author":"Ishida","year":"2018","journal-title":"Int. J. Hematol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"172","DOI":"10.5045\/br.2018.53.2.172","article-title":"Peripheral neuropathy associated with imatinib therapy for chronic myeloid leukemia","volume":"53","author":"Kavanagh","year":"2018","journal-title":"Blood Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.2169\/internalmedicine.4824-20","article-title":"Dasatinib-induced Reversible Demyelinating Peripheral Neuropathy and Successful Conversion to Nilotinib in Chronic Myelogenous Leukemia","volume":"59","author":"Inoue","year":"2020","journal-title":"Intern. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1177\/1352458519892914","article-title":"CNS demyelination after initiating the tyrosine kinase inhibitor imatinib: A report of two cases","volume":"26","author":"Rotstein","year":"2020","journal-title":"Mult. Scler."},{"key":"ref_74","first-page":"3679319","article-title":"Nilotinib-Induced Dystonia and Cognitive Deficits in a Neurologically Normal Patient with Chronic Myeloid Leukemia","volume":"2019","author":"Chan","year":"2019","journal-title":"Case Rep. Neurol. Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.htct.2019.01.003","article-title":"A case of neurocognitive deficit strongly related to dasatinib therapy","volume":"42","author":"Chamoun","year":"2020","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1080\/10428194.2020.1855340","article-title":"Adverse events among chronic myelogenous leukemia patients treated with tyrosine kinase inhibitors: A real-world analysis of health plan enrollees","volume":"62","author":"Chow","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Yu, L., Huang, X., Gale, R.P., Wang, H., and Jiang, Q. (2019). Variables associated with patient-reported symptoms in persons with chronic phase chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy. Medicine, 98.","DOI":"10.1097\/MD.0000000000018079"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/17474086.2021.1852924","article-title":"Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: A critical review of the current practice","volume":"13","author":"Breccia","year":"2020","journal-title":"Expert Rev. Hematol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.3109\/10428194.2012.666545","article-title":"Secondary malignancy after imatinib therapy: Eight cases and review of the literature","volume":"53","author":"Duman","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Kumar, V., Garg, M., Chaudhary, N., and Chandra, A.B. (2018). An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States. PeerJ, 6.","DOI":"10.7717\/peerj.4342"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1038\/leu.2016.20","article-title":"Secondary malignancies in chronic myeloid leukemia patients after imatinib-based treatment: Long-term observation in CML Study IV","volume":"30","author":"Miranda","year":"2016","journal-title":"Leukemia"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s11899-017-0404-z","article-title":"Chronic Myeloid Leukemia-the Promise of Tyrosine Kinase Inhibitor Discontinuation","volume":"12","author":"Narra","year":"2017","journal-title":"Curr Hematol. Malig. Rep."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"192","DOI":"10.5152\/eajm.2011.42","article-title":"Serious skin reaction associated with imatinib in a patient with chronic myeloid leukemia","volume":"43","author":"Albayrak","year":"2011","journal-title":"Eurasian J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.clml.2016.09.012","article-title":"Pleural Effusion in Dasatinib-Treated Patients with Chronic Myeloid Leukemia in Chronic Phase: Identification and Management","volume":"17","author":"Cortes","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/bjh.13346","article-title":"Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era","volume":"169","author":"Gunnarsson","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_86","first-page":"197","article-title":"A Corpus with Multi-Level Annotations of Patients, Interventions and Outcomes to Support Language Processing for Medical Literature","volume":"2018","author":"Nye","year":"2018","journal-title":"Proc. Conf. Assoc. Comput. Linguist Meet."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Allegri, S.A., McCoy, K., and Mitchell, C.S. (2022). CompositeView: A Network-Based Visualization Tool. Big Data Cogn. Comput., 6.","DOI":"10.3390\/bdcc6020066"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4686\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:39:58Z","timestamp":1760143198000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/14\/19\/4686"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,26]]},"references-count":87,"journal-issue":{"issue":"19","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["cancers14194686"],"URL":"https:\/\/doi.org\/10.3390\/cancers14194686","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,26]]}}}